Litcius/Paper detail

Efficacy and safety of osilodrostat in patients with Cushing's disease (LINC 3): a multicentre phase III study with a double-blind, randomised withdrawal phase

Rosario Pivonello, Maria Fleseriu, John Newell‐Price, Xavier Bertagna, James W. Findling, Akira Shimatsu, Feng Gu, Richard J. Auchus, Rattana Leelawattana, Eun Jig Lee, Jung Hee Kim, André Lacroix, Audrey Laplanche, P.R. O'Connell, Libuse Tauchmanovà, Alberto M Pedroncelli, Beverly M. K. Biller

2020The Lancet Diabetes & Endocrinology211 citationsDOI

Topics & Concepts

MedicineCushing's diseaseInternal medicineClinical trialGastroenterologySurgeryDiseasePituitary Gland Disorders and TreatmentsAdrenal Hormones and DisordersGrowth Hormone and Insulin-like Growth Factors